Product

Quaratusugene Ozeplasmid

Aliases

quaratusugene ozeplasmid, Reqorsa

2 clinical trials

3 indications

Indication

Indication

Non-Small Cell Lung

Indication

Extensive-Stage Small Cell Lung Cancer

Clinical trial

A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer

Status: Recruiting, Estimated PCD: 2026-12-01

Clinical trial

A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Status: Recruiting, Estimated PCD: 2026-02-01